Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

25.38 -2.38

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

24.8

Maximum

25.84

Fő mutatók

By Trading Economics

Bevétel

191K

-51M

Értékesítés

6.7M

106M

Egy részvényre jutó nyereség

-0.46

Profit margin

-47.808

Munkavállalók

1,784

EBITDA

-2.1M

-46M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+25.58% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

593M

2.6B

Előző nyitás

27.76

Előző zárás

25.38

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 12. 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

2026. aug. 12. 23:56 UTC

Social Media
News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

2026. aug. 12. 23:51 UTC

News

Fossil Group Inc reported second-quarter sales of $209.7 million, exceeding expectations. Shares are trading sharply higher in after-market hours.

2026. aug. 12. 23:51 UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

2026. aug. 12. 23:51 UTC

Social Media
News

Harmonic Inc. reported strong Q2 results, with adjusted EPS of $0.24 and raised full-year guidance, leading shares higher in after-market hours.

2026. aug. 12. 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

2026. aug. 12. 23:46 UTC

News

Cummins shares are higher in after-market trading following strong Q2 earnings of $9.46 billion, surpassing analyst expectations despite an adjusted EPS miss.

2026. aug. 12. 23:46 UTC

News

Wendy's shares declined in after-market hours after earlier gains on news of a potential buyout bid from Nelson Peltz's Trian Fund Management.

2026. aug. 12. 23:41 UTC

News

Granite Construction secures a $31 million contract for the Willow Rock Energy Storage Center, boosting its project portfolio. Shares are higher in after-market trading.

2026. aug. 12. 23:41 UTC

News

Mistras Group raised its fiscal year revenue guidance to $740-$755 million, driving shares higher in after-market trading. Adjusted EBITDA is expected around $93.5 million.

2026. aug. 12. 23:41 UTC

News
Social Media

Jack in the Box Inc. reports third-quarter earnings with EPS of $1.08, exceeding expectations. The stock is trading higher in after-market hours.

2026. aug. 12. 23:41 UTC

Social Media
News

EnerSys reported strong first-quarter results, with adjusted EPS of $3.66 and revenue of $935.6 million. Shares are higher in after-market trading.

2026. aug. 12. 23:41 UTC

News
Social Media

Coherent Corp shares fell in after-hours trading despite strong fourth-quarter results, including adjusted EPS of $1.74 and revenue of $2.05 billion.

2026. aug. 12. 23:41 UTC

Social Media
News

Enovix Corp shares are lower in after-market hours following mixed second-quarter results and lower-than-expected third-quarter revenue guidance.

2026. aug. 12. 23:36 UTC

Social Media
News

Cheniere Energy raised its 2026 earnings and production guidance despite a quarterly loss. Shares are higher in after-market trading amid rising natural gas prices.

2026. aug. 12. 23:36 UTC

News

Alexandria Real Estate Equities has priced a $1 billion offering of 7.250% junior subordinated notes, with shares modestly higher in after-market trading.

2026. aug. 12. 23:36 UTC

News

Nasdaq Inc. shares gained in after-market trading, reaching a monthly high as inflation data eased concerns over Federal Reserve rate hikes.

2026. aug. 12. 23:26 UTC

News

Red Robin Gourmet Burgers shares rose in after-market trading following a Q2 earnings report that showed adjusted earnings and revenue exceeding analyst expectations.

2026. aug. 12. 23:26 UTC

News

Trian Fund Management increased its stake in GE Healthcare Technologies to 3.1 million shares, contributing to a modest rise in after-market hours.

2026. aug. 12. 23:26 UTC

News
Correlated Moves

Vishay Intertechnology announced a quarterly dividend of $0.10 per share, enhancing investor sentiment as shares trade higher in after-market hours.

2026. aug. 12. 23:21 UTC

News

Duke Energy has restored power to over 171,000 customers in Greater Cincinnati. Shares are gaining in after-market hours amid this progress.

2026. aug. 12. 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

2026. aug. 12. 23:11 UTC

News

Goldman Sachs will acquire NEOS Investments for up to $2.25 billion, enhancing its asset management division with new income ETFs. Shares are higher in after-market trading.

2026. aug. 12. 23:06 UTC

News

Spero Therapeutics reports FDA approval of Utebzi and secures $105 million financing. Shares are trading higher in after-market hours.

2026. aug. 12. 23:06 UTC

News
Social Media

Meta Platforms faces a federal trial over youth safety violations. In after-market trading, shares are slightly higher despite ongoing legal challenges.

2026. aug. 12. 23:06 UTC

News

Phillips 66 shares rose in after-market trading following a strong second-quarter performance and a $10 billion increase in buyback authorization.

2026. aug. 12. 23:06 UTC

News

FormFactor Inc will participate in key investor conferences, boosting market interest. Shares are higher in after-market trading following the announcement.

2026. aug. 12. 23:06 UTC

Social Media
News

NextEra Energy has secured a $3.3 billion investment for natural gas projects in Texas and Pennsylvania, though shares are trading lower in after-market hours.

2026. aug. 12. 23:02 UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

2026. aug. 12. 23:01 UTC

News

Kimball Electronics shares are lower in after-market trading following a quarterly adjusted EPS loss of $0.01, missing expectations of $0.39.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

25.58% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 32.65 USD  25.58%

Magas 45 USD

Alacsony 21.6 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

4 ratings

3

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat